FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time

  The biopharmaceutical company Cellectar Biosciences recently announced that the FDA granted its lead phospholipid drug conjugate, CLR 131, Orphan Drug Designation(ODD) for treatment of lymphoplasmacytic lymphoma. ODD is granted by…

Continue Reading FDA Grants Orphan Drug Designation to Cellectar’s CLR 131 for the Sixth Time
Company Releases Early Clinical Data For Experimental Blood Cancer Drug
SarahMarciano / Pixabay

Company Releases Early Clinical Data For Experimental Blood Cancer Drug

According to a story from pm360online.com, the biopharmaceutical company miRagen Therapeutics, Inc., recently presented Phase I clinical trial data regarding the company's experimental drug cobomarsen. This data was presented at…

Continue Reading Company Releases Early Clinical Data For Experimental Blood Cancer Drug

FDA Approves a Combination of Drugs for Diffuse Large B-cell Lymphoma

  Diffuse large B-cell lymphoma  (DLBCL) is a common type of non-Hodgkins lymphoma. World Pharma News recently reported that the FDA approved the first chemoimmunotherapy, Polivy, for DLBCL in combination with…

Continue Reading FDA Approves a Combination of Drugs for Diffuse Large B-cell Lymphoma
FDA Grants Fast Track Designation to Diffuse Large B-Cell Lymphoma Drug Candidate
https://pixabay.com/en/thumbs-up-okay-good-well-done-2056022/

FDA Grants Fast Track Designation to Diffuse Large B-Cell Lymphoma Drug Candidate

According to a press release from the New Jersey-based biotechnology company Cellectar Biosciences, the Food and Drug Administration (FDA) has granted "Fast Track" designation to the Company's experimental diffuse large…

Continue Reading FDA Grants Fast Track Designation to Diffuse Large B-Cell Lymphoma Drug Candidate

Accelerated Approval Granted to a Novel Drug Combination That Treats Patients with a Common Type of Non-Hodgkin Lymphoma

  Each year over eighteen thousand people in the United States are diagnosed with diffuse large B-cell lymphoma (DLBCL) a common type of non-Hodgkin lymphoma. A recent FDA news release…

Continue Reading Accelerated Approval Granted to a Novel Drug Combination That Treats Patients with a Common Type of Non-Hodgkin Lymphoma

Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders

According to a story from PR Newswire, presentations at the 60th annual American Society of Hematology Meeting and Exposition are highlighting the results of four large scale clinical trials that…

Continue Reading Presentations Demonstrate Promising Advances in Blood Cancers and Blood Disorders
Study Highlights The Need For Precision in CAR-T Cell Therapies
allinonemovie / Pixabay

Study Highlights The Need For Precision in CAR-T Cell Therapies

According to a story from MedCity News, a recent study revealed a potential weakness of CAR-T cell immunotherapies that reveals the need for precision and caution in the extraction process.…

Continue Reading Study Highlights The Need For Precision in CAR-T Cell Therapies
NZ Patient With Diffuse Large B Cell Lymphoma Fundraising to Travel to US For Treatment
Holgi / Pixabay

NZ Patient With Diffuse Large B Cell Lymphoma Fundraising to Travel to US For Treatment

According to a story from stuff.co.nz., Janelle Brunton-Rennie and Kurt Brunton were celebrating their third wedding anniversary this past January. Little did they know that the next day, their lives…

Continue Reading NZ Patient With Diffuse Large B Cell Lymphoma Fundraising to Travel to US For Treatment
Close Menu